Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Methylation & Proteomics-Based Detection of Bladder Cancer

Methylation & Proteomics-Based Detection of Bladder Cancer

226
Cairns, PaulFox Chase Cancer Center
Feng, ZidingFred Hutchinson Cancer Research Center

No involved investigator sites defined.

Study never launched
Hypermethylation
Prostate and Urologic Cancers Research Group
1

Study never Launched

This study will test the sensitivity of gene methylation in the presence of clinically evident, pathologically confirmed bladder cancer. This study will test the specificity of gene methylation in two groups of participants without bladder cancer - requiring cystoscopy for hematuria and for foreign body (urinary stones, stents, and catheters) or infection.
Quantitative real time methylation specific PCR (qMSP) of urine sediment DNA using a panel of several methylated gene markers.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.

Announcement 01/30/2017

Please visit http://www.compass. fhcrc.org/meeting/reg_edrn/edrnsc.aspx for information and to register for the 31st EDRN Steering Committee Meeting in Tempe, AZ, from March 6-9, 2017.

Announcement